Medicaid coverage of GLP-1s for weight loss, by state
| State | Medicaid, weight loss | What the rule says | Programs we confirmed ship there |
|---|---|---|---|
| Delaware | Covered (prior authorization) | Covered with prior authorization: adults BMI >= 30, or BMI 27-30 with a weight-related condition (DMAP PA form, revised 4/2026). Fee-for-service;… | 8 |
| Kansas | Covered (prior authorization) | Covered with prior authorization for adult obesity (Saxenda, Wegovy, Zepbound) per KDHE anti-obesity criteria; KFF lists Kansas as covering (Jan 2026). | 8 |
| Minnesota | Covered (prior authorization) | Covered with prior authorization (Saxenda, Wegovy, Zepbound; BMI and renewal rules). A 2026 bill to end coverage (HF 4142, would start 2027) was laid over… | 8 |
| Mississippi | Covered (prior authorization) | Covered with prior authorization; adult criteria effective 7/1/2026 name Foundayo, Saxenda, Wegovy and Zepbound and require an obesity treatment plan. | 5 |
| Missouri | Covered (prior authorization) | Covered with prior authorization; Foundayo, Zepbound and Zepbound KwikPen preferred, Wegovy non-preferred (needs a medical-necessity reason). Adults BMI >=… | 8 |
| North Carolina | Covered (prior authorization) | Covered with prior approval. Coverage stopped Oct 1, 2025 and was reinstated Dec 12, 2025 (NC Medicaid Direct and Managed Care). Wegovy preferred; Zepbound… | 8 |
| Tennessee | Covered (prior authorization) | Covered with prior authorization since Aug 1, 2025 (TennCare weight management agents PA form, 08/2026); Wegovy and Zepbound preferred. MCOs add wraparound… | 8 |
| Wisconsin | Covered (prior authorization) | Covered with prior authorization. From July 1, 2026 a new weight management drug class: Foundayo and Zepbound preferred, PA required for all, one agent at a… | 8 |
| Michigan | Limited | Since Jan 1, 2026 (MDHHS letter L 25-73, budget cut): only for morbid obesity, after documented failure of other weight-loss treatments including preferred… | 8 |
| Virginia | Limited | Service authorization only (form effective 10/20/2026): BMI > 40, or > 37 with dyslipidemia, hypertension or type 2 diabetes, plus a failed trial of a… | 8 |
| Alabama | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 7 |
| Alaska | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Arizona | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Arkansas | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| California | Not covered for obesity | Medi-Cal ended GLP-1 coverage for weight loss on Jan 1, 2026. | 8 |
| Colorado | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Connecticut | Not covered for obesity | KFF (Jan 2026, fee-for-service): covers one or more non-GLP-1 weight-loss drugs, but no GLP-1s for obesity. | 8 |
| District of Columbia | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. (DC is included in KFF's map.) | 0 |
| Florida | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Georgia | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Hawaii | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Idaho | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Illinois | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Indiana | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. Indiana announced in July 2026 that it is joining the federal BALANCE model to cover Wegovy,… | 8 |
| Iowa | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Kentucky | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Louisiana | Not covered for obesity | KFF (Jan 2026, fee-for-service): covers one or more non-GLP-1 weight-loss drugs, but no GLP-1s for obesity. Act 898 of 2026 (SB 433, effective June 9, 2026)… | 5 |
| Maine | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Maryland | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Massachusetts | Not covered for obesity | MassHealth stopped covering GLP-1s and other drugs prescribed solely for weight loss in early July 2026 (MassHealth bulletin: July 3, 2026); about 22,000… | 8 |
| Montana | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Nebraska | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Nevada | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| New Hampshire | Not covered for obesity | Ended Jan 1, 2026 for prescriptions solely for weight loss. KFF notes NH still covers one or more non-GLP-1 weight-loss drugs. | 8 |
| New Jersey | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| New Mexico | Not covered for obesity | KFF (Jan 2026, fee-for-service): covers one or more non-GLP-1 weight-loss drugs, but no GLP-1s for obesity. | 8 |
| New York | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| North Dakota | Not covered for obesity | KFF (Jan 2026, fee-for-service): covers one or more non-GLP-1 weight-loss drugs, but no GLP-1s for obesity. | 8 |
| Ohio | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Oklahoma | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Oregon | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Pennsylvania | Not covered for obesity | Ended Jan 1, 2026 for adults 21 and older (under-21 pathway kept). KFF notes PA still covers one or more non-GLP-1 weight-loss drugs. | 8 |
| Rhode Island | Not covered for obesity | Ended Oct 1, 2026 under the FY2027 budget: Foundayo, Saxenda, Wegovy and Zepbound no longer covered when prescribed solely for weight loss. | 8 |
| South Carolina | Not covered for obesity | Ended Jan 1, 2026 (coverage for Saxenda and Wegovy had started Nov 1, 2024). | 8 |
| South Dakota | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Texas | Not covered for obesity | KFF (Jan 2026, fee-for-service): covers one or more non-GLP-1 weight-loss drugs, but no GLP-1s for obesity. | 8 |
| Utah | Not covered for obesity | The one-year fee-for-service pilot (July 1, 2025 to June 30, 2026) was not renewed; obesity-only coverage ended June 30, 2026 (Medicaid Information… | 8 |
| Vermont | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Washington | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| West Virginia | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
| Wyoming | Not covered for obesity | KFF (Jan 2026, fee-for-service): not covered for obesity. | 8 |
Sources: each state's Medicaid pharmacy pages and KFF's Medicaid GLP-1 survey (January 2026), checked Nov 3, 2026; managed-care plans can add their own criteria. Program counts are programs we compare that state on their own site that they serve the state.
What "covered" means in Medicaid
Where Medicaid covers Wegovy or Zepbound for weight loss, it is never automatic. Expect prior authorization with a recent BMI (usually 30 or more, or 27 with a weight-related condition), sometimes proof of a diet or lifestyle program, and renewal every 6 to 12 months with proof of weight loss. Some states prefer one drug: Missouri covers Zepbound and Foundayo but not Wegovy for weight loss; Wisconsin and Tennessee list preferred products.
Managed-care plans, which cover most Medicaid members, follow the state rules but use their own forms. Ask your plan's member services for the "anti-obesity medication" criteria.
States that cut coverage in 2026
Budgets pushed several states the other way. California's Medi-Cal ended GLP-1 coverage for weight loss on January 1, 2026; Massachusetts (MassHealth) stopped in July 2026; Michigan narrowed it to severe obesity after other treatments fail. North Carolina stopped in October 2025 and brought coverage back in December. Coverage can change quickly, which is why we date every row.
If your state doesn't cover it
Medicaid still covers GLP-1s like Ozempic and Mounjaro if you have type 2 diabetes, so mention that diagnosis if it applies. Otherwise the realistic route is self-pay. Compounded semaglutide starts at $59 a month and compounded tirzepatide at $96 at the programs we compare (Nov 12, 2026); month to month, the lowest semaglutide is $59 at SnagRx. Several accept HSA or FSA cards.
Check that the program ships to your state first: a few skip Louisiana, Mississippi or Alabama because of state rules on compounded GLP-1s. The table above counts the programs we confirmed for each state.






